Zepbound Pens

Zepbound is a weekly injectable medication that is used for treating patients who struggle with obesity (BMI ≥30) or who are overweight (BMI ≥27) with one or more weight-related comorbidities. This medication has also been approved for treating moderate-to-severe obstructive sleep apnea in adults who struggle with obesity. There are already thousands of patients filling their prescriptions at Insulin Outlet. Patients doing so can get Zepbound pens and other similar medications from licensed Canadian pharmacy partners and receive up to 80% savings compared to typical U.S. prices. This helps make essential medications more affordable to those who need them.

Zepbound is a prescription medication that works as both a GIP and GLP-1 receptor agonist. This medication is prescribed to patients with obesity (BMI of at least 30 kg/m²) to help them lose weight. It is also sometimes used for those who are overweight (BMI of at least 27 kg/m²) and have been diagnosed with a weight-related condition. Zepbound has also been approved for use in treating patients with obesity who struggle with moderate to severe OSA. This medication comes in a couple of different injectable forms and is taken weekly by the patient.

• Some studies show that Zepbound users often lose more weight than those taking other mono GLP-1 medications like Wegovy
• This medication impacts both GIP and GLP-1 receptors in the body
• Zepbound may also be helpful for treating those with OSA in addition to obesity
• This medication only needs to be taken once per week

There are several different strengths and doses available for Zepbound users. Single-dose pen and vial versions of Zepbound can be found in the following strengths:

• 2.5 mg/0.5 mL
• 5 mg/0.5 mL
• 7.5 mg/0.5 mL
• 10 mg/0.5 mL
• 12.5 mg/0.5 mL
• 15 mg/0.5 mL

Each of the multi-dose vials or single-patient-use KwikPens has four doses of the medication within them. These devices are offered in the following strengths:

• 10 mg/2.4 mL (4 doses of 2.5 mg/0.6 mL)
• 20 mg/2.4 mL (4 doses of 5 mg/0.6 mL)
• 30 mg/2.4 mL (4 doses of 7.5 mg/0.6 mL)
• 40 mg/2.4 mL (4 doses of 10 mg/0.6 mL)
• 50 mg/2.4 mL (4 doses of 12.5 mg/0.6 mL)
• 60 mg/2.4 mL (4 doses of 15 mg/0.6 mL)

Patients using the KwikPen version of Zepbound can do so by:

1. Prepare
   • Wash hands
   • Check the pen label and expiration date
   • Make sure the solution is clear to slightly yellow with no particles
2. Attach Needle
   • Remove pen cap
   • Clean the rubber seal with alcohol
   • Attach a new needle and remove both caps
3. Prime the Pen (before first use)
   • Dial to the priming setting (as instructed)
   • Hold pen upright and tap to move air bubbles up
   • Press the dose knob until a drop appears at the needle tip
   • Repeat if needed (up to 3 times) and replace needle if unsuccessful
4. Set Dose
   • Turn the dose knob until the prescribed dose is displayed
5. Inject
   • Inject into abdomen (≥2 inches from navel), thigh, or upper arm
   • Insert needle into skin
   • Press and hold the dose knob until “0” appears, then count to 5
6. After Injection
   • Remove needle from skin
   • Apply light pressure if needed (do not rub)
   • Recap, remove, and dispose of the needle in a sharps container
   • Replace pen cap (do not store with needle attached)

Those using the single-patient-use pens will have to follow a different set of instructions.

1. Prepare
   • Wash hands and choose an injection site (rotate weekly)
2. Set Up
   • Keep pen locked
   • Remove base cap (do not touch needle)
3. Inject
   • Place pen flat against skin
   • Unlock the pen
   • Press and hold the injection button for up to 10 seconds
   • Listen for 2 clicks (start and completion)
4. After Injection
   • Make sure the plunger is visible in the window
   • Remove pen and dispose of it in a sharps container

The vial versions also use a separate set of instructions.

1. Prepare
   • Wash hands
   • Clean vial stopper with alcohol
2. Draw Dose
   • Attach needle (if needed)
   • Draw air into syringe equal to prescribed dose
   • Insert needle into vial and inject air.
   • Turn vial upside down and withdraw the correct dose
   • Remove air bubbles and adjust to exact dose
3. Inject
   • Inject into abdomen, thigh, or upper arm
   • Push plunger fully and hold for at least 5 seconds
4. After Injection
   • Remove needle and apply gentle pressure if needed
   • Dispose of syringe and needle in a sharps container

All needles and devices used to administer Zepbound should be properly disposed of after use.

Boxed Warning

Zepbound has a boxed warning for the potential cause of C-cell tumors – including medullary thyroid carcinoma (as experienced in some rodent studies). The human relevance of these findings is still undetermined. This treatment is not recommended for patients with a personal or family history of MTC. It is also contraindicated in those who have been diagnosed with Multiple Endocrine Neoplasia type 2. Patients should also refrain from taking this medication if they have a known serious hypersensitivity to the medication or any of its ingredients.

This medication may also cause serious gastrointestinal problems in some patients. Use of this medication is not advised for patients with severe gastroparesis. Renal function should also be monitored for patients using this medication since it may lead to kidney injury in some rare cases. Gallbladder issues have been reported in some instances for patients using this medication in clinical trials. Further testing is recommended if any indications of cholecystitis appear.

Cases of acute pancreatitis have occurred in patients taking GLP-1 medications. Patients should stop Zepbound if there are signs of pancreatitis. Serious hypersensitivity reactions have also occurred in some cases during postmarketing use of tirzepatide. Patients with these issues should seek immediate medical attention and stop taking the medication.

Risk of hypoglycemia increases when this medication is used with insulin or insulin-stimulating medications (it is uncommon when used alone). Dose adjustments may be required. Patients with a history of diabetic retinopathy should be monitored for worsening symptoms. These issues are more common for patients with type 2 diabetes. There have been rare reports of pulmonary aspiration while using Zepbound around the time of general anesthesia or deep sedation. Patients should let their healthcare team know before having surgery. Pens and devices should never be shared between patients – even if the needle is changed.

Common Side Effects

The most commonly experienced side effects for patients taking Zepbound include:

• Fatigue
• Belching
• Nausea
• Injection site reactions
• Stomach pain
• Diarrhea
• Allergic reactions
• Constipation
• Vomiting
• Indigestion
• Heartburn
• Hair loss

Studies show that side effects like nausea/vomiting and diarrhea usually occur during dose increases and typically decrease on their own over time. Patients with persistent or severe side effects should talk to their doctor.

Severe Side Effects

This medication can also lead to severe side effects in some less common cases. This includes side effects such as severe stomach problems or stomach problems that do not go away. It may also include severe side effects such as kidney problems. However, these issues usually occur as a result of dehydration from loss of fluids and staying hydrated can help reduce the likelihood of developing these issues.

Patients who miss a dose of this medication should take the missed dose as soon as possible as long as it is still within four days of when it was originally scheduled to be taken. Patients should skip their missed dose if it has been longer than those four days and resume their regular dosing schedule as normal at the next scheduled time. A maximum of 15 mg of this medication can be taken per week. Patients who overdose on this medication should contact the Poison Help Line (by calling 1-800-222-1222) or a medical toxicologist. This line is specific to patients located in the U.S.

Single-dose pens – as well as single-dose vials – variations of Zepbound should be kept in a refrigerated environment at a temperature of 36°F to 46°F – equivalent to storing between 2°C and 8°C. This medication may be kept at room temperature up to 86°F (the equivalent of 30°C) for up to 21 days before it should be discarded (do not place back in the refrigerator after doing so).

Multi-dose vials and single-patient-use KwikPens may be stored in the refrigerator or at room temperature. Discard after 30 days at room temperature/30 days after first use or after 4 weekly doses – whichever comes first. Keep this medication out of conditions where it may become frozen or exposed to direct sunlight.

Patients buying their medication from Insulin Outlet experience:

• Up to 80% savings on their medication’s U.S. prices
• Real medications from licensed Canadian pharmacies
• Flat $29.99 cold shipping
• Medications and services with a 4.9-star average rating from more than 4,000 users

Buy Zepbound pens from Canada today.